Rainer Lueoend

A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice

Ulf Neumann, Heinrich Rueeger, Rainer Machauer et al. · Molecular Neurodegeneration · 2015 · 109 citations · Full text

Discovery of Cyclic Sulfone Hydroxyethylamines as Potent and Selective β-Site APP-Cleaving Enzyme 1 (BACE1) Inhibitors: Structure-Based Design and in Vivo Reduction of Amyloid β-Peptides

Heinrich Rueeger, Rainer Lueoend, Olivier Rogel et al. · Journal of Medicinal Chemistry · 2012 · 98 citations · Full text

Pharmaceutical Science, Core Scaffold Selection, Peptide Science +23

Assessment of the active-site requirements of 5-aminolevulinic acid dehydratase: evaluation of substrate and product analogs as competitive inhibitors

Rainer Lueoend, Josef Walker, Reinhard Neier · The Journal of Organic Chemistry · 1992 · 32 citations

Pharmaceutical Science, Altmetric Attention Score, Pharmacotherapy +21

Discovery of Umibecestat (CNP520): A Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor for the Prevention of Alzheimer’s Disease

Rainer Machauer, Rainer Lueoend, Konstanze Hurth et al. · Journal of Medicinal Chemistry · 2021 · 32 citations · Full text

Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: Structure based design and in vivo reduction of amyloid β-peptides

Heinrich Rueeger, Rainer Lueoend, Rainer Machauer et al. · Bioorganic & Medicinal Chemistry Letters · 2013 · 24 citations · Full text

Biochemistry, Medicine, Natural Sciences +9